10-K: Insmed Reports Strong Revenue Growth, Expands Pipeline

Insmed Incorporated reported significant revenue growth in 2025 driven by the launch of BRINSUPRI and international ARIKAYCE sales, alongside substantial investments in its clinical pipeline and R&D.

Summary

• Total product revenues, net, increased by 66.7% to $606.4 million in 2025, up from $363.7 million in 2024.
• BRINSUPRI, an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB), was approved in the US in August 2025 and in the EU in November 2025, contributing $172.7 million in US sales.
• ARIKAYCE sales grew by 19.3% to $433.8 million, with international sales increasing by 40.9% to $153.5 million.
• Net loss for 2025 was $1,276.8 million, an increase from $913.8 million in 2024, reflecting significant R&D and commercialization investments.
• Research and Development (R&D) expenses rose by 28.9% to $771.1 million, primarily due to increased headcount, manufacturing expenses, and the $40.0 million acquisition of INS1148.
• Selling, General and Administrative (SG&A) expenses increased by 52.1% to $701.2 million, driven by commercial and commercial readiness activities for BRINSUPRI.
• The ENCORE trial for ARIKAYCE, aimed at supporting full approval and label expansion for all MAC lung disease patients, completed enrollment with 425 patients in Q4 2024.
• A Phase 3 study of TPIP in patients with Pulmonary Arterial Hypertension (PAH) is planned for H1 2026, following positive Phase 2b results showing a 35% reduction in pulmonary vascular resistance (PVR) and a 35.5-meter improvement in 6-minute walk distance (6MWD).
• The Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) completed enrollment, with topline data anticipated in Q2 2026.
• INS1148, a Phase 2-ready monoclonal antibody targeting SCF248, was acquired in December 2025, with Phase 2 development programs planned for interstitial lung disease and moderate to severe asthma.
• Phase 1 clinical studies for gene therapies INS1201 (Duchenne muscular dystrophy) and INS1202 (amyotrophic lateral sclerosis) are ongoing and continue to enroll patients.
• The company maintains a strong liquidity position with $510.4 million in cash and cash equivalents and $919.6 million in marketable securities as of December 31, 2025.
• The Mikaela Naylon Give Kids a Chance Act, reauthorizing the Rare Pediatric Disease Priority Review Voucher (PRV) Program through 2029, was signed into law on February 3, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While the significant increase in net loss is a concern, it is largely attributable to aggressive, strategic investments in R&D and commercialization following key product approvals and pipeline advancements. The strong revenue growth and multiple positive clinical milestones indicate a company actively executing its growth strategy, albeit at a high cost in the short term.

Positives

• Total product revenues, net, increased by 66.7% to $606.4 million in 2025, demonstrating strong commercial execution.
• BRINSUPRI received US FDA approval in August 2025 and EU EC approval in November 2025, marking successful commercial launches in key markets.
• ARIKAYCE international sales grew significantly by 40.9% in 2025, contributing to overall revenue growth.
• Positive topline results from the ARISE trial validated the QOL-B respiratory domain as an effective PRO tool for MAC lung disease.
• Enrollment for the pivotal ENCORE trial for ARIKAYCE was completed in Q4 2024, with topline data expected by April 2026, potentially leading to full approval and label expansion.
• TPIP showed positive Phase 2b results in PAH, including a 35% reduction in PVR and a 35.5-meter improvement in 6MWD, supporting progression to Phase 3.
• TPIP received Orphan Drug Designation from the FDA for PAH in January 2026.
• The acquisition of INS1148 in December 2025 adds a Phase 2-ready monoclonal antibody to the pipeline, targeting interstitial lung disease and moderate to severe asthma.
• Ongoing Phase 1 studies for gene therapies INS1201 (DMD) and INS1202 (ALS) indicate continued advancement in novel therapeutic areas.
• The company successfully raised $823.3 million in net proceeds from an equity offering in June 2025, strengthening its capital position.

Negatives

• Net loss increased significantly to $1,276.8 million in 2025 from $913.8 million in 2024, indicating continued unprofitability.
• R&D expenses increased by 28.9% to $771.1 million, reflecting high costs associated with clinical trials and asset acquisitions.
• SG&A expenses increased by 52.1% to $701.2 million, driven by substantial commercialization costs for BRINSUPRI.
• The brensocatib Phase 2b BiRCh study in chronic rhinosinusitis without nasal polyps (CRSsNP) failed to meet its primary or secondary efficacy endpoints, leading to discontinuation of the program for this indication.
• The company has a history of operating losses since 2010 and does not anticipate achieving profitability in the foreseeable future.
• ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients exceeding 50,000.
• BRINSUPRI is likely to be subject to Medicare Drug Price Negotiation under the Inflation Reduction Act (IRA) in the future, potentially impacting pricing and revenue.

Risks

• Failure to successfully commercialize ARIKAYCE and BRINSUPRI or maintain their approvals.
• Inability to obtain full approval of ARIKAYCE from the US FDA, including timely completion of the confirmatory post-marketing clinical trial (ENCORE).
• Failure to obtain, or delays in obtaining, regulatory approvals for product candidates or label expansions for existing products.
• Uncertainties or changes in market acceptance of marketed products or product candidates by physicians, patients, and payors.
• Inability to obtain and maintain adequate reimbursement or acceptable prices from government or third-party payors.
• Inaccuracies in estimates of potential market sizes for products and product candidates.
• Failure of third-party manufacturers or clinical trial partners to meet commercial or clinical needs or comply with regulations.
• Risks associated with senior secured loan and royalty financing agreements, including covenant compliance and operational restrictions.
• Inability to create or maintain an effective direct sales and marketing infrastructure or partner with third parties.
• Failure to successfully conduct future clinical trials, including patient enrollment and retention challenges.
• Development of unexpected safety or efficacy concerns related to marketed products or product candidates, especially for gene therapies.
• Delays in clinical studies, identification of serious side effects, or rejection of protocol amendments.
• Failure to successfully predict the time and cost of development, regulatory approval, and commercialization for novel gene therapy products.
• Risk that interim, topline, or preliminary data from clinical trials may change or be interpreted differently.
• Risk of competitors obtaining orphan drug exclusivity for similar products.
• Inability to attract and retain key personnel or effectively manage growth.
• Inability to successfully integrate acquisitions or commercialize acquired technologies.
• Inability to adapt to a highly competitive and changing environment.
• Inability to access, upgrade, or expand technology systems or difficulties in implementing new technology.
• Risk of losing significant customers.
• Adverse effects from healthcare legislation or other government action, including drug pricing reforms.
• Business or economic disruptions due to catastrophes, natural disasters, or public health crises.
• Risks associated with the current and potential future use of artificial intelligence (AI) and machine learning.
• Inability to adequately protect intellectual property rights or prevent disclosure of trade secrets.
• Failure to comply with obligations in third-party agreements, potentially leading to loss of license rights.
• Exposure to costly intellectual property disputes.
• Product liability claims and limited product liability insurance coverage.
• Material disruption or reputational harm from system failures, security breaches, or cyber-attacks.
• Violations of data protection laws and regulations.
• History of operating losses and the possibility of never achieving or maintaining profitability.
• Need to raise additional funds and potential inability to obtain capital on acceptable terms.
• Adverse effects from outstanding indebtedness and potential future indebtedness, including restrictive covenants and dilution.
• Inability to use certain net operating losses and other tax assets due to ownership changes.
• Goodwill impairment charges affecting financial results.
• Shareholders experiencing dilution from future issuance of additional common stock.
• Volatility in stock price potentially leading to shareholder litigation.
• Certain provisions of Virginia law, articles of incorporation, and bylaws may hamper third-party acquisition attempts.

Future Outlook

The company anticipates continued substantial operating losses in the near term as it funds R&D for its pipeline programs (ARIKAYCE confirmatory trial, TPIP, brensocatib in HS, INS1148, INS1201, INS1202), continues commercialization and regulatory activities for ARIKAYCE and BRINSUPRI, and engages in general and administrative activities. Topline data from the ENCORE trial for ARIKAYCE is expected by April 2026, with a US sNDA submission projected for H2 2026, potentially supporting label expansion. Regulatory decisions for brensocatib in NCFB in the UK and Japan are anticipated in 2026. Phase 3 studies for TPIP in PAH, PPF, and IPF are expected to be initiated in H1 and H2 2026, respectively. Topline data from the Phase 2b CEDAR study of brensocatib in HS is expected in Q2 2026. The company expects R&D and SG&A expenses to increase in 2026.

Management Comments

• We are a people-first global biopharmaceutical company striving to deliver firstand best-in-class therapies to transform the lives of patients facing serious diseases.
• Our key priorities are to ensure successful US commercial launch of BRINSUPRI, continue to provide ARIKAYCE to appropriate patients and expand its label, advance our pipeline and produce topline clinical data readouts, and control spending by prudently deploying capital.
• We believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, but may raise additional capital to fund future development and acquisitions.

Industry Context

StockSavvy.ai notes that Insmed operates in highly competitive biopharmaceutical and gene therapy sectors, characterized by rapid technological change and significant R&D costs. The successful commercialization of BRINSUPRI in NCFB, where no other approved therapies exist in the US, Europe, or Japan, positions Insmed as a first-mover. The expansion of ARIKAYCE's label and pipeline advancements in rare respiratory, immunology, and neurodegenerative diseases (DMD, ALS) align with broader industry trends focusing on unmet medical needs and specialized therapies. However, the increasing scrutiny on drug pricing, particularly with the Inflation Reduction Act (IRA) potentially impacting BRINSUPRI, reflects a challenging reimbursement landscape. The company's reliance on third-party manufacturing and the evolving regulatory environment for gene therapies are common industry challenges.

Comparison to Industry Standards

• BRINSUPRI's approval in the US and EU for NCFB positions it as a first-in-class therapy, as no other approved treatments for bronchiectasis are known in these regions or Japan. This provides a significant competitive advantage compared to companies developing therapies for indications with established competitors.
• The positive Phase 2b results for TPIP in PAH, showing a 35% reduction in PVR and a 35.5-meter improvement in 6MWD, are competitive within the PAH landscape, which includes other treprostinil formulations. The once-daily dosing profile of TPIP aims to offer a differentiated product profile by easing treatment burden and potentially reducing side effects compared to existing inhaled prostanoid therapies that require 4-9 doses per day.
• ARIKAYCE's accelerated approval for refractory MAC lung disease and its inclusion in international treatment guidelines highlight its role in a niche market with limited alternatives, distinguishing it from broader antibiotic treatments.
• The company's gene therapy programs (INS1201 for DMD, INS1202 for ALS) are in early Phase 1 development, a stage where many competitors also have programs. The intrathecal delivery approach for DMD aims to target both skeletal and cardiac muscles at lower doses than intravenous gene therapies, potentially offering a differentiated safety and efficacy profile compared to competitors like Sarepta Therapeutics (SRP-9001) or Pfizer (PF-06939926) which use intravenous delivery for DMD gene therapy.
• The acquisition of INS1148, a Phase 2-ready monoclonal antibody, demonstrates a strategy of external innovation to complement internal R&D, a common practice among biopharmaceutical companies to diversify and accelerate pipeline development.

Corporate Governance

Legal Proceedings

• The company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business, but management does not expect the ultimate costs to have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

Stakeholder Impact

• **Shareholders**: Experience dilution from recent and potential future equity offerings, but also benefit from strong revenue growth and pipeline advancements that could drive long-term value. Increased net losses and high R&D/SG&A expenses impact short-term profitability.
• **Patients**: Benefit from new treatment options like BRINSUPRI for NCFB and potential label expansion for ARIKAYCE, as well as ongoing development of therapies for serious rare diseases (PH-ILD, PAH, HS, DMD, ALS).
• **Employees**: Benefit from continued growth, expansion of development and commercial capabilities, and equity compensation plans designed to attract and retain talent. Increased headcount in 2025 reflects growth opportunities.
• **Third-Party Payors**: Face new reimbursement considerations with the launch of BRINSUPRI and potential label expansion of ARIKAYCE, with ongoing negotiations and potential impact from drug pricing legislation like the IRA.
• **Suppliers/Manufacturers**: Continued reliance on a small number of third-party manufacturers (Resilience, Patheon, Esteve, PARI) for commercial and clinical supply, indicating ongoing business for these partners.

Next Steps

• Report topline data from the ENCORE trial for ARIKAYCE by April 2026.
• Submit a US supplementary new drug application (sNDA) for ARIKAYCE in all MAC lung disease patients in the second half of 2026.
• Review ENCORE data with Japan's Pharmaceuticals and Medical Devices Agency to support potential label expansion in Japan.
• Anticipate regulatory decisions for brensocatib for NCFB in the United Kingdom (UK) and Japan in 2026.
• Initiate a Phase 3 study of TPIP in patients with PAH in the first half of 2026.
• Report data from the open-label extension (OLE) of the Phase 2b study of TPIP in PAH in the second half of 2026.
• Initiate additional Phase 3 studies of TPIP in patients with PPF and IPF in the second half of 2026.
• Advance Phase 2 development programs for INS1148 initially in interstitial lung disease and moderate to severe asthma.
• Report topline data from the Phase 2b CEDAR study of brensocatib in HS in the second quarter of 2026.
• Continue to enroll patients in the Phase 1 ASCEND clinical study of INS1201 for DMD.
• Continue to enroll patients in the Phase 1 ARMOR clinical study of INS1202 for ALS.
• Evaluate potential effect of evolving US policies on timing for future potential international commercial launches of BRINSUPRI.
• Continue to explore additional opportunities utilizing various technologies within Respiratory, Immunology & Inflammation, and Neuro & Other Rare therapeutic areas.
• Continue to hire additional personnel to support ARIKAYCE and BRINSUPRI and advance clinical and pre-clinical programs in 2026.

Key Dates

Recommendation

Insmed is in a high-growth, high-investment phase, marked by significant revenue increases from new product launches and international expansion, alongside substantial R&D and commercialization expenses leading to increased net losses. The robust clinical pipeline with multiple upcoming data readouts and new asset acquisitions presents considerable long-term potential. However, the current unprofitability, reliance on capital raises, and inherent risks in drug development and commercialization warrant a 'hold' recommendation. Investors should monitor the outcomes of key clinical trials (ENCORE, TPIP Phase 3, CEDAR) and the company's path to profitability, as these will be critical determinants of future stock performance.

Keywords

Biopharmaceutical, Rare Diseases, Respiratory, Immunology & Inflammation, Neuro & Other Rare, ARIKAYCE, BRINSUPRI, MAC Lung Disease, Non-Cystic Fibrosis Bronchiectasis, NTM Lung Disease, TPIP, Pulmonary Hypertension, Interstitial Lung Disease, PAH, PPF, IPF, Brensocatib, DPP1 Inhibitor, Hidradenitis Suppurativa, INS1148, Stem Cell Factor 248, Gene Therapy, Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, INS1201, INS1202, SEC Filing, 10-K, Clinical Trials, Regulatory Approval, Orphan Drug, FDA, EC, MHLW, Commercialization, Biotechnology, Pharmaceuticals